Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013.
Charokopou M, Sabater FJ, Townsend R, Roudaut M, McEwan P, Verheggen BG. Charokopou M, et al. Among authors: verheggen bg. Curr Med Res Opin. 2016;32(2):207-18. doi: 10.1185/03007995.2015.1102722. Epub 2015 Dec 3. Curr Med Res Opin. 2016. PMID: 26473650 Review.
The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective.
Charokopou M, Vioix H, Verheggen BG, Bratt T, Franks D. Charokopou M, et al. Among authors: verheggen bg. Value Health. 2014 Nov;17(7):A343. doi: 10.1016/j.jval.2014.08.689. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200638 Free article. No abstract available.
Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective.
Charokopou M, Vioix H, Verheggen BG, Dillon S, Franks D. Charokopou M, et al. Among authors: verheggen bg. Value Health. 2014 Nov;17(7):A343. doi: 10.1016/j.jval.2014.08.690. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200640 Free article. No abstract available.
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective.
Charokopou M, Vioix H, Verheggen BG, Maddocks D, Bratt T, Franks D. Charokopou M, et al. Among authors: verheggen bg. Value Health. 2014 Nov;17(7):A344-5. doi: 10.1016/j.jval.2014.08.696. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200644 Free article. No abstract available.
Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Charokopou M, Vioix H, Eddowes LA, Griffiths M, Verheggen BG, Gabriel Z, Tolley K. Charokopou M, et al. Among authors: verheggen bg. Value Health. 2014 Nov;17(7):A347. doi: 10.1016/j.jval.2014.08.710. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200660 Free article. No abstract available.
Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
Verheggen BG, Lee R, Lieuw On MM, Treur MJ, Botteman MF, Kaplan SA, Trocio JN. Verheggen BG, et al. J Med Econ. 2012;15(3):586-600. doi: 10.3111/13696998.2012.666511. Epub 2012 Feb 24. J Med Econ. 2012. PMID: 22332704 Free article.
24 results